Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Azercabtagene zapreleucel (azer-cel)

Phase 1Cell therapy

TTG Therapeutics, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

B-Cell Mediated Autoimmune DisordersRecruiting

B-Cell Mediated Autoimmune DisordersPhase 1

Recruiting

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

B-Cell Mediated Autoimmune Disorders

NCT06680037

Clinical

Trials by Indication[1]

B-cell Mediated Autoimmune Disorders1 trial

A Phase 1, Open-label Study to Evaluate the Safety and Clinical Activity of Azercabtagene Zapreleucel in Participants With B-cell Mediated Autoimmune Disorders

Recruiting·TTG Therapeutics, Inc.·Phase 1·NCT06680037·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Azercabtagene zapreleucel (azer-cel). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azercabtagene zapreleucel (azer-cel) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azercabtagene zapreleucel (azer-cel). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TG Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: TTG Therapeutics, Inc.

Related News